Induction Chemotherapy

"Induction Chemotherapy" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Initial drug treatment designed to bring about REMISSION INDUCTION. It is typically a short-term and high-dose drug treatment that is followed by CONSOLIDATION CHEMOTHERAPY and then MAINTENANCE CHEMOTHERAPY.

Descriptor ID	D060828
MeSH Number(s)	E02.319.499 E02.860.500
Concept/Terms	Induction Chemotherapy Induction Chemotherapy Chemotherapies, Induction Chemotherapy, Induction Induction Chemotherapies

Below are MeSH descriptors whose meaning is more general than "Induction Chemotherapy".

Analytical, Diagnostic and Therapeutic Techniques and Equipment [E]
Therapeutics [E02]
Drug Therapy [E02.319]
Induction Chemotherapy [E02.319.499]
Remission Induction [E02.860]
Induction Chemotherapy [E02.860.500]

Below are MeSH descriptors whose meaning is related to "Induction Chemotherapy".

Below are MeSH descriptors whose meaning is more specific than "Induction Chemotherapy".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Induction Chemotherapy" by people in this website by year, and whether "Induction Chemotherapy" was a major or minor topic of these publications.

Bar chart showing 17 publications over 9 distinct years, with a maximum of 4 publications in 2016 and 2018

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2011	1	0	1
2012	0	1	1
2013	0	1	1
2014	1	0	1
2015	1	0	1
2016	2	2	4
2018	2	2	4
2020	1	0	1
2021	0	3	3

Below are the most recent publications written about "Induction Chemotherapy" by people in Profiles.

Sidana S, Kumar S, Fraser R, Estrada-Merly N, Giralt S, Agrawal V, Anderson LD, Aljurf M, Banerjee R, Bashey A, Battiwalla M, Beitinjaneh A, Chakraborty R, Chhabra S, Dhakal B, Dholaria B, Hashmi S, Janakiram M, Lee C, Lekakis L, Murthy HS, Parrondo R, Wangjam T, Usmani S, Shah N, Qazilbash M, D'Souza A. Impact of Induction Therapy with VRD versus VCD on Outcomes in Patients with Multiple Myeloma in Partial Response or Better Undergoing Upfront Autologous Stem Cell Transplantation. Transplant Cell Ther. 2022 02; 28(2):83.e1-83.e9.

View in: PubMed
Schulte R, Hinson A, Huynh V, Breese EH, Pierro J, Rotz S, Mixon BA, McNeer JL, Burke MJ, Orgel E. Levocarnitine for pegaspargase-induced hepatotoxicity in older children and young adults with acute lymphoblastic leukemia. Cancer Med. 2021 11; 10(21):7551-7560.

View in: PubMed
Foureau D, Bhutani M, Guo F, Rigby K, Leonidas M, Tjaden E, Fox A, Atrash S, Paul B, Voorhees PM, Usmani SZ. Comparison of mass spectrometry and flow cytometry in measuring minimal residual disease in multiple myeloma. Cancer Med. 2021 10; 10(20):6933-6936.

View in: PubMed
Whittle SB, Smith V, Silverstein A, Parmeter M, Minard CG, Bernhardt MB, Zage PE, Venkatramani R, Nuchtern JG, Heczey A, Russell HV, Shohet JM, Foster JH. Is high-risk neuroblastoma induction chemotherapy possible without G-CSF? A pilot study of safety and treatment delays in the absence of primary prophylactic hematopoietic growth factors. Pediatr Blood Cancer. 2020 10; 67(10):e28417.

View in: PubMed
Saini NY, Cerny J, Furtado VF, Desmond A, Zhou Z, Raffel G, Puthawala I, Bednarik J, Shanahan L, Miron PM, Woda B, Ramanathan M, Nath R. Elderly do benefit from induction chemotherapy: High dose mitoxantrone-based ("5 + 1") induction chemotherapy regimen in newly diagnosed acute myeloid leukemia. Am J Hematol. 2019 02; 94(2):209-215.

View in: PubMed
Martin SA, Chiodo LM, Bosse JD, Wilson A. The Next Stage of Buprenorphine Care for Opioid Use Disorder. Ann Intern Med. 2018 11 06; 169(9):628-635.

View in: PubMed
Weinstein C, Jordan K, Green SA, Camacho E, Khanani S, Beckford-Brathwaite E, Pong A, Noga SJ, Rapoport BL. Evaluation of factors contributing to the response to fosaprepitant in a heterogeneous, moderately emetogenic chemotherapy population: an exploratory analysis of a randomized phase III trial. Support Care Cancer. 2018 Nov; 26(11):3773-3780.

View in: PubMed
Dhakal B, Szabo A, Chhabra S, Hamadani M, D'Souza A, Usmani SZ, Sieracki R, Gyawali B, Jackson JL, Asimakopoulos F, Hari PN. Autologous Transplantation for Newly Diagnosed Multiple Myeloma in the Era of Novel Agent Induction: A Systematic Review and Meta-analysis. JAMA Oncol. 2018 Mar 01; 4(3):343-350.

View in: PubMed
Rodriguez V, Kairalla J, Salzer WL, Raetz EA, Loh ML, Carroll AJ, Heerema NA, Wood BL, Borowitz MJ, Burke MJ, Asselin BL, Devidas M, Winick NJ, Carroll WL, Hunger SP, Dreyer ZE. A Pilot Study of Intensified PEG-Asparaginase in High-risk Acute Lymphoblastic Leukemia: Children's Oncology Group Study AALL08P1. J Pediatr Hematol Oncol. 2016 08; 38(6):409-17.

View in: PubMed
Sun W, Orgel E, Malvar J, Sposto R, Wilkes JJ, Gardner R, Tolbert VP, Smith A, Hur M, Hoffman J, Rheingold SR, Burke MJ, Wayne AS. Treatment-related adverse events associated with a modified UK ALLR3 induction chemotherapy backbone for childhood relapsed/refractory acute lymphoblastic leukemia. Pediatr Blood Cancer. 2016 11; 63(11):1943-8.

View in: PubMed

People

Explore

Similar Concepts

Top Journals